Clinical trials: Chemotherapy-induced Neutropenia
Chemotherapy-induced Neutropenia
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
The primary purpose of this study is to compare the percentage of patients with Duration of Severe Neutropenia (DSN) =0 in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus…
- Trial name
- NCT03294577
- Testing
- Pegfilgrastim, Plinabulin, Docetaxel, doxorubicin, and cyclophosphamide (TAC)
- Where
- 20 sites in China, Ukraine
- Volunteers
- 221 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Chemotherapy-induced Neutropenia
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
The primary purpose of this study is to compare the duration of severe neutropenia (DSN) in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus Docetaxel, doxorubicin, and…
- Trial name
- NCT04227990
- Testing
- Plinabulin, Pegfilgrastim, Docetaxel, doxorubicin, and cyclophosphamide (TAC)
- Where
- 11 sites in China, Ukraine
- Volunteers
- 115 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Chemotherapy-Induced Febrile Neutropenia
Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
The goal of this real-world study is to compare the efficacy and safety of QL0605 administered 24 hours and 48 hours after chemotherapy in breast cancer patients.
- Trial name
- NCT06616571
- Testing
- QL0605(PEG-rhG-CSF)
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Chemotherapy-Induced Neutropenia
Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)
A Phase III Randomized Controlled Open Label Comparative Multicentric Trial To Compare The Safety And Efficacy of Indigenous Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) With Neupogen In Patients on…
- Trial name
- NCT00776165
- Testing
- Recombinant Human GCSF (Shantha Biotechnics Limited), Neupogen
- Where
- 7 sites in India
- Volunteers
- 126 people
- Sponsor
- Shantha Biotechnics Limited
Chemotherapy-induced Neutropenia
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer
The purpose of the present trial is to evaluate the safety, tolerability and pharmacokinetics(PK)/pharmacodynamics(PD) of single subcutaneous injection of GW003 in breast cancer patients.
- Trial name
- NCT02725606
- Testing
- Pegylated Recombinant Human G-CSF, GW003
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Chemotherapy-induced Neutropenia
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
To assess the duration of severe neutropenia (DSN) in treatment Cycle 1 in patients treated with docetaxel (75 mg/m2) + plinabulin (5, 10, or 20 mg/m2) or with docetaxel (75 mg/m2) + pegfilgrastim (6 mg).
- Trial name
- NCT04345900
- Testing
- Plinabulin, Pegfilgrastim
- Where
- 19 sites in United States, China and 2 more
- Volunteers
- 55 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Chemotherapy Induced Neutropenia
GCPGC in Chemotherapy-induced Neutropenia
This study is adaptive design and it consists of stage I and stage II. Stage I is multi-center, parallel-group, single-blind, phase II study to determine the adequate dose of GCPGC in chemotherapy-induced neutropenia.
- Trial name
- NCT01328938
- Testing
- GCPGC 3.6mg, GCPGC 6mg, Neulasta (pegfilgrastim) 6mg
- Where
- 15 sites in South Korea
- Volunteers
- 177 people
- Sponsor
- Green Cross Corporation
Chemotherapy-Induced Neutropenia, Myelosuppression
Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia
Neutropenia is the most serious hematologic toxicity of cancer chemotherapy, often limiting the doses and density of chemotherapy that can be tolerated. The degree and duration of neutropenia determine the risk of infection.
- Conditions
- Chemotherapy-Induced Neutropenia, Myelosuppression, Breast Cancer
- Trial name
- MyeloConcept (NCT02692742)
- Testing
- Myelo001
- Where
- 23 sites in Germany
- Volunteers
- 137 people
- Sponsor
- Myelo Therapeutics GmbH
Neutropenia, Breast Cancer
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
The purpose of this study was to compare the efficacy of a single dose of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the duration of…
- Trial name
- ADVANCE (NCT02643420)
- Testing
- SPI-2012, Pegfilgrastim, Docetaxel
- Where
- 81 sites in United States, Canada and 1 more
- Volunteers
- 406 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Neutropenia, Breast Cancer
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
The purpose of this study is to compare the efficacy of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) as measured by the duration of severe neutropenia…
- Trial name
- NCT02953340
- Testing
- SPI-2012, Pegfilgrastim, Docetaxel
- Where
- 74 sites in United States, Canada and 4 more
- Volunteers
- 237 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Neutropenia
Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients
To assess the duration of severe neutropenia in cycle 1 of chemotherapy after treatment with a single injection of KRN125 or multiple daily injections of filgrastim.
- Trial name
- NCT00364468
- Testing
- pegfilgrastim
- Where
- 6 sites in Japan
- Volunteers
- 107 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Febrile Neutropenia
Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer
To assess the safety and establish the dose to assess the pharmacokinetic activity following administration of EC-18 in patients with advanced breast cancer receiving low febrile neutropenia risk chemotherapy who are the…
- Trial name
- NCT03104595
- Testing
- EC-18
- Where
- 3 sites in South Korea
- Volunteers
- 28 people
- Sponsor
- Enzychem Lifesciences Corporation
Stage III Colorectal Cancer, Neutropenia
A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.
This is a randomized, double-blind, placebo-controlled multi-center phaseⅢstudy to evaluate efficacy and safety of oxaliplatin-based chemotherapy plus MB-6(320 mg/capsule, 6 capsules tid) in patients with stage 3 colorectal…
- Trial name
- MB-6 (NCT02135887)
- Testing
- MB-6
- Where
- Taiwan
- Volunteers
- 184 people
- Sponsor
- Microbio Co Ltd
Neoplasms (no Otherwise Specified)
A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen
Primary Objective: To evaluate the incidence and severity of neutropenia in patients being treated for solid tumours with a Taxotere® based regimen when Granocyte® 34 is being used as a primary prophylaxis for…
- Trial name
- Grano-Tax (NCT01107756)
- Testing
- LENOGRASTIM (GRANOGYTE 34)
- Where
- 25 sites in South Africa
- Volunteers
- 403 people
- Sponsor
- Sanofi
Colorectal Cancer Metastatic, Myelosuppression-Adult
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
This was a randomized, double-blind, placebo-controlled, global, multicenter, Phase 3 trial evaluating the impact of trilaciclib on myelopreservation and anti-tumor efficacy when administered prior to FOLFOXIRI/bevacizumab in…
- Conditions
- Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
- Trial name
- PRESERVE1 (NCT04607668)
- Testing
- Trilaciclib
- Where
- 82 sites in United States, China and 6 more
- Volunteers
- 326 people
- Sponsor
- G1 Therapeutics, Inc.
Chemotherapy-induced Neutropenia
Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects
This study is designed to access the tolerability and Pharmacokinetic/Pharmacodynamic (PK/PD) of single subcutaneous (SC) injection of GW003 in healthy subjects.
- Trial name
- NCT02643901
- Testing
- GW003
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Neutropenia, Chemotherapy-Induced Febrile, Breast Neoplasm Female
Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy
To evaluate the efficacy, safety, and immunogenicity of PEG-G-CSF Injection (Kexing Biopharmaceutical Co., Ltd.) for the prevention of neutropenia after chemotherapy, using the PEG-G-CSF Injection ( Neulasta®, Amgen Europe B.V.)…
- Trial name
- NCT06711523
- Testing
- PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.), PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Kexing Biopharm Co., Ltd.
Chemotherapy-induced Neutropenia
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced or metastatic breast cancer, who have failed >/= 1 but < 5 prior lines of chemotherapy; locally advanced or metastatic non small cell…
- Trial name
- Protective-1 (NCT03102606)
- Testing
- Plinabulin, Pegfilgrastim
- Where
- 18 sites in United States, China and 2 more
- Volunteers
- 105 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Extensive-stage Small-cell Lung Cancer
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.
- Trial name
- NCT05874401
- Testing
- Trilaciclib, Topotecan
- Where
- Spain
- Volunteers
- 302 people
- Sponsor
- Pharmacosmos A/S
Chemotherapy-Induced Neutropenia, Breast Cancer
Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy
This is an investigation of the safety and efficacy of Maxy-G34 in breast cancer patients treated with TAC chemotherapy. Maxy-G34 will be given as a single injection during each cycle of chemotherapy, for a planned total of six…
- Trial name
- NCT00501332
- Testing
- Maxy-G34
- Where
- 15 sites in Poland, Romania and 2 more
- Volunteers
- 30 people
- Sponsor
- Maxygen Holdings Ltd.